Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Representative image of allied health students in a medical training session as HCA Healthcare’s CHCP deal highlights the growing battle to build the next clinical workforce.
Pharma & Biotech

HCA Healthcare’s CHCP acquisition puts clinical workforce training at the center of hospital growth

HCA Healthcare’s CHCP deal turns allied health education into a strategic workforce lever as hospitals confront staffing pressure.

Read More
Representative image of liver disease drug research and clinical data analysis. Zydus’ FDA Priority Review for saroglitazar highlights the growing treatment competition in primary biliary cholangitis.
Pharma & Biotech

Zydus gains FDA Priority Review for saroglitazar as PBC treatment competition intensifies

Zydus’ saroglitazar gets FDA Priority Review in PBC, setting up a key test for dual PPAR therapy in rare liver disease.

Read More
Representative image of clinical research teams reviewing trial performance data as ICON plc’s restatement raises wider questions over CRO trust and pharma outsourcing risk.
Features & Analysis

Can ICON turn governance repair into renewed momentum for clinical research services?

ICON’s restatement and backlog reset test CRO confidence as pharma sponsors weigh execution risk, trial demand and 2026 recovery signals.

Read More
Representative image of oncology biomarker testing and antibody-drug conjugate research. Antengene’s ATG-022 Phase III clearance highlights rising competition in CLDN18.2-targeted treatment for advanced gastric and gastroesophageal junction cancer.
Pharma & Biotech

Why CLINCH-3 matters for Antengene’s oncology strategy and gastric cancer ambitions

Antengene’s ATG-022 enters pivotal testing in gastric cancer, testing whether CLDN18.2 ADCs can stand out in a crowded oncology field.

Read More
Representative image of proteomics data analysis as Seer’s takeover pressure puts diagnostics platforms, biomarker discovery and life sciences technology value in focus.
Medical Devices & Diagnostics

Why the Radoff-JEC bid for Seer is bigger than a small-cap biotech takeover fight

Find out why Seer’s activist battle could reshape investor thinking on proteomics, diagnostics platforms and biotech value creation.

Read More
Representative image of cardiovascular drug research and RNA-based therapeutic development. Ribo’s RBD1119 Phase 2 filing highlights growing interest in siRNA antithrombotic strategies for coronary artery disease.
Pharma & Biotech

Ribo’s coronary artery disease filing highlights the next frontier for RNA-based cardiovascular drugs

Ribo’s RBD1119 Phase 2 filing could test whether siRNA drugs can reduce coronary artery disease risk without bleeding trade-offs.

Read More
Representative image of MRI brain scan analysis as Ono Pharmaceutical’s ONO-2808 trial data highlights new research momentum in multiple system atrophy treatment.
Pharma & Biotech

Why Ono’s Phase 2 MSA data may matter beyond one World Parkinson Congress poster

Ono’s ONO-2808 data hints at disease modification in MSA. See why Phase 3 may decide whether the signal becomes a breakthrough.

Read More
Representative image of pharmaceutical manufacturing and respiratory medicine research. Lupin Limited’s China approval for oseltamivir phosphate oral suspension highlights the continuing role of paediatric-friendly antiviral formulations in influenza treatment access.
Pharma & Biotech

Can Lupin use oseltamivir approval to deepen its China respiratory medicine strategy?

Lupin’s China approval adds a paediatric-friendly flu antiviral to its portfolio. See why formulation and access still matter in generics.

Read More
Representative image of a cancer care specialist reviewing gastroesophageal scan data as BeOne Medicines’ HER2-positive gastroesophageal cancer results draw attention after ASCO 2026.
Pharma & Biotech

Could BeOne’s zanidatamab regimen reset expectations in HER2-positive gastroesophageal cancer?

Find out how BeOne’s HERIZON-GEA data could reshape HER2-positive gastroesophageal cancer treatment after ASCO 2026.

Read More
Representative image of oncology research and blood cancer diagnostics. AbbVie’s DECNUPAZ approval highlights how CD123-targeted antibody-drug conjugates could reshape treatment options for blastic plasmacytoid dendritic cell neoplasm.
Pharma & Biotech

How AbbVie’s DECNUPAZ approval changes the treatment conversation in aggressive BPDCN

Find out how AbbVie’s DECNUPAZ approval could change BPDCN treatment while raising new safety and adoption questions.

Read More